Results 21 to 30 of about 8,165 (189)

Screening of DUB activity and specificity by MALDI-TOF mass spectrometry [PDF]

, 2014
Deubiquitylases (DUBs) are key regulators of the ubiquitin system which cleave ubiquitin moieties from proteins and polyubiquitin chains. Several DUBs have been implicated in various diseases and are attractive drug targets. We have developed a sensitive
A Iphofer, A Kovalenko, A van der Horst, AC Faesen, AK Al-Hakim, AM Oliveira, B Nicholson, C Kondapalli, C Reverdy, D Bungert, D Komander, D Komander, D Komander, DW Lee, E Graner, E Szajli, EW Harhaj, F Colland, F El Oualid, F Ikeda, FE Reyes-Turcu, G Nicastro, H Mistry, HB Kramer, J Chen, J Hemelaar, J Liang, J McCullough, JF McGouran, JW Pierce, K Keusekotten, K Saigoh, L Daviet, LC Dang, LV Pham, M Altun, M Colombo, M Karas, M Li, M Pulvino, MJ Clague, MJ Lee, MK Hospenthal, N Krishnan, NL Anderson, OW Huang, P Cohen, P Rufenacht, R Ekkebus, RA Horton, S Strickson, S Virdee, SD Sherrod, SJ Orcutt, SM Nijman, SM Nijman, SP Shah, TE Messick, TE Mevissen, U Hassiepen, Y Liu, Y Takano, Y Zhang   +62 more
core   +3 more sources

Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis

Arthritis Research & Therapy, 2018
Background The purpose of this study was to assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults.
Jasvinder A. Singh, John D. Cleveland
doaj   +1 more source

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study

Therapeutic Advances in Musculoskeletal Disease, 2022
Background: To evaluate the safety, tolerability, and efficacy of SHR4640, a highly selective urate transporter-1 inhibitor, in combination with febuxostat, in patients with primary hyperuricemia.
Honghu Tang, Beibei Cui, Yiyu Chen, Lin Chen, Zhihong Wang, Ning Zhang, Yanlan Yang, Xiaodong Wang, Xiangliang Xie, Lingyun Sun, Wantai Dang, Xianyang Wang, Runzi Li, Jianjun Zou, Yi Zhao, Yi Liu   +15 more
doaj   +1 more source

Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK. [PDF]

, 2013
Excess reactive oxygen species (ROS) formation can trigger various pathological conditions such as inflammation, in which xanthine oxidase (XO) is one major enzymatic source of ROS.
Busso, N., Ives, A., Nomura, J., So, A., Tamura, M., Tsujimoto, S., Yamanaka, Y.   +6 more
core   +3 more sources

Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease

Scientific Reports, 2023
Hyperuricemia relates to chronic kidney disease (CKD) progression and impaired endothelial function. Febuxostat is potent and effective for decreasing serum uric acid levels.
Naowanit Nata, Nanthawut Ninwisut, Pitchamon Inkong, Ouppatham Supasyndh, Bancha Satirapoj   +4 more
doaj   +1 more source

Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death. [PDF]

, 2015
Leydig cells are crucial to the production of testosterone in males. It is unknown if the cancer chemotherapeutic drug, 6-mercaptopurine (6 MP), produces Leydig cell failure among adult survivors of childhood acute lymphoblastic leukemia. Moreover, it is
Bao, Ju, Chemaitilly, Wassim, Frase, Sharon, Green, Daniel M, Janke, Laura, Lynch, John, Morgan, Jessica A, Opferman, Joseph T, Panetta, John C, Schuetz, John D, Wang, Yao, Zheng, Jie   +11 more
core   +1 more source

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout

Rheumatology and Therapy, 2019
Introduction This 24-week randomized, double-blind, non-inferiority study compared the efficacy and safety of febuxostat, a xanthine oxidase inhibitor, with allopurinol using an up-titration method in hyperuricemic Chinese subjects with or without gout ...
Fengchun Zhang, Zhichun Liu, Lindi Jiang, Hao Zhang, Dongbao Zhao, Yang Li, Hejian Zou, Xiaoyue Wang, Xiangpei Li, Bingyin Shi, Jianhua Xu, Hongjie Yang, Shaoxian Hu, Shen Qu   +13 more
doaj   +1 more source

The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout

Journal of International Medical Research, 2020
Objective To measure the effect of febuxostat on the serum levels of uric acid (sUA) and the proinflammatory cytokines interleukin (IL)-6, IL-17 and tumour necrosis factor-α (TNF-α) in Chinese Han patients with gout and hyperuricaemia.
Yuan-Yuan Huang, Zhuang Ye, San-Wei Gu, Zhen-Yu Jiang, Ling Zhao   +4 more
doaj   +1 more source

Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation. [PDF]

, 2015
Activation of the NLRP3 inflammasome by microbial ligands or tissue damage requires intracellular generation of reactive oxygen species (ROS). We present evidence that macrophage secretion of IL1β upon stimulation with ATP, crystals or LPS is mediated by
Busso, N., Ives, A., LeRoy, D., Martinon, F., Miner, J.N., Nomura, J., Roger, T., Simon, G., So, A.   +8 more
core   +1 more source

Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial

Journal of International Medical Research, 2021
Objective Heart failure (HF) is a common and highly morbid cardiovascular disorder. Oxidative stress worsens HF, and uric acid (UA) is a useful oxidative stress marker.
Satoshi Suzuki, Akiomi Yoshihisa, Tetsuro Yokokawa, Atsushi Kobayashi, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Akihiro Tsuda, Tatsunori Tsuda, Toshiyuki Ishibashi, Ichiro Konno, Osamu Yamaguchi, Hirofumi Machii, Naoki Nozaki, Takeshi Niizeki, Takuya Miyamoto, Yasuchika Takeishi,   +17 more
doaj   +1 more source